Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 6990.HK · Stock Open Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. in new tab
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Analysis (6990.HK)
Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. a good investment? Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) is currently trading at 522.50 HKD. Market analysts have a consensus price target of 570.05 HKD. This suggests a potential upside from current levels.
Earnings Schedule: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is expected to release its next earnings report on Aug. 24, 2026. The market consensus estimate for Forward EPS is 3.57.
Investor FAQ
Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 24, 2026. The company currently has a trailing EPS of -1.93.
Company Profile
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally. The company's product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Community Discussion